189 related articles for article (PubMed ID: 28628634)
1. Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms.
Fania C; Arosio B; Capitanio D; Torretta E; Gussago C; Ferri E; Mari D; Gelfi C
PLoS One; 2017; 12(6):e0179280. PubMed ID: 28628634
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease.
Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A
J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
5. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.
Kitamura Y; Usami R; Ichihara S; Kida H; Satoh M; Tomimoto H; Murata M; Oikawa S
Neurol Res; 2017 Mar; 39(3):231-238. PubMed ID: 28107809
[TBL] [Abstract][Full Text] [Related]
6. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
Laske C; Stransky E; Fritsche A; Eschweiler GW; Leyhe T
Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
10. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.
Dumurgier J; Vercruysse O; Paquet C; Bombois S; Chaulet C; Laplanche JL; Peoc'h K; Schraen S; Pasquier F; Touchon J; Hugon J; Lehmann S; Gabelle A
Alzheimers Dement; 2013 Jul; 9(4):406-13. PubMed ID: 23141384
[TBL] [Abstract][Full Text] [Related]
11. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
12. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
Mouton-Liger F; Paquet C; Dumurgier J; Lapalus P; Gray F; Laplanche JL; Hugon J;
Biol Psychiatry; 2012 May; 71(9):829-35. PubMed ID: 22281122
[TBL] [Abstract][Full Text] [Related]
13. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.
Vafadar-Isfahani B; Ball G; Coveney C; Lemetre C; Boocock D; Minthon L; Hansson O; Miles AK; Janciauskiene SM; Warden D; Smith AD; Wilcock G; Kalsheker N; Rees R; Matharoo-Ball B; Morgan K
J Alzheimers Dis; 2012; 28(3):625-36. PubMed ID: 22045497
[TBL] [Abstract][Full Text] [Related]
14. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.
Russell CL; Mitra V; Hansson K; Blennow K; Gobom J; Zetterberg H; Hiltunen M; Ward M; Pike I
J Alzheimers Dis; 2017; 55(1):303-313. PubMed ID: 27636850
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
Kang K; Ko PW; Jin M; Suk K; Lee HW
J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
